ImmunoCellular Therapeutics Ltd (NYSEAMERICAN:IMUC) Makes A Move That Inspires Hope Among Cancer Patients

Sula Iron Eyes A Brighter With Plans To Change Gear With The DRC Cobalt License
December 19, 2017
Ampio Pharmaceuticals Inc (NYSEAMERICAN:AMPE) Announces That Ampion Met Its Primary Endpoint
December 19, 2017

ImmunoCellular Therapeutics Ltd (NYSEAMERICAN:IMUC) Makes A Move That Inspires Hope Among Cancer Patients

The stock of ImmunoCellular Therapeutics Ltd (NYSEAMERICAN:IMUC) closed at $0.328 losing 18.61% in yesterday’s trading session. It is great news for most of the cancer patients around the globe after they learnt about the most recent development in the company. ImmunoCellular Therapeutics is already through with its first step towards the production of the unlimited killer T Cells targeted at destroying cancerous cells.

The latest development is a major step forward for the company which has over the years sought out for mechanisms to help it stimulate the immune systems of patients to facilitate the production of killer T cells. These cells pose quite minimal side effects in the process of destroying the various tumor cells. This is apparently a working technique when it comes to the facing out of the various types of cancers.

The company’s spokesperson said, “The research team at ImmunoCellular successfully packaged a T cell receptor (TCR) DNA sequence into a lentiviral vector, which was then used to transfect human hematopoietic stem cells. The Company has been able to verify successful transfer of genetic material into the stem cells.”

He proceeded to outline that they had plans underway to move on with their efforts aimed at optimizing the transfection process. The company affirmed that the completion of the phase of the Stem-to-T-Cell development was a critical component in their business operations. Great progress was being made towards preclinical testing and the future looks promising.

The Senior Vice President, Steven J. Swanson, made his remarks. He outlined that they had put much focus on their Stem-to-T-Cell program adding that they were happy for having achieved such a critical initial milestone. Together with their collaborators they are scheduling plans to undertake the next move which is about the enhancement of the transfection process.

He outlined that they were going to remain dedicated to their vision of developing working solutions for the intractable cancers. That would move along way towards enhancing the lives of patients as they continue looking forward to a potential cure in the near future. According to him, they were at the verge of establishing a program that would be a game-changer in the treatment of cancer.

Comments are closed.